| Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. | |
| | |
MedLine Citation:
|
PMID: 17565920 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study was undertaken to evaluate the ocular hypotensive efficacy of brimonidine Purite 0.15% (Alphagan P 0.15%; Allergan, Inc., Irvine, Calif) given as adjunctive therapy with latanoprost 0.005% (Xalatan; Pfizer Inc., New York, NY( to patients with open-angle glaucoma or ocular hypertension. In this multicenter, open-label, prospective evaluation, the intraocular pressure (IOP) of the 43 enrolled patients was > or =18 mm Hg after at least 6 wk of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect )10 AM, or approximately 2 h after the morning dose of brimonidine 0.15%(. IOP at trough drug effect (8 AM, or approximately 12 h after the evening dose of brimonidine) was also measured. Baseline IOP was 21.9 (+/-2.3) mm Hg. After 1 mo of treatment, additional mean IOP reductions from latanoprost-treated baseline values were 5.8 mm Hg (26%) at peak drug effect (P<.001) and 3.3 mm Hg (15%) at trough (P<.001). At the month 2 visit, additional mean IOP reductions from latanoprost-treated baseline values were 5.1 mm Hg (23%) at peak drug effect (P<.001) and 2.0 mm Hg (9%) at trough (P=.002). Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from latanoprost-treated baseline values. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients given latanoprost who require additional lowering of IOP. |
| | |
Authors:
|
Thomas Mundorf; Robert J Noecker; Melissa Earl |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Advances in therapy Volume: 24 ISSN: 0741-238X ISO Abbreviation: Adv Ther Publication Date: 2007 Mar-Apr |
Date Detail:
|
Created Date: 2007-06-13 Completed Date: 2007-07-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 302-9 Citation Subset: T |
Affiliation:
|
Private Practice, Charlotte, NC, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antihypertensive Agents / administration & dosage, adverse effects, therapeutic use* Drug Therapy, Combination Female Glaucoma, Open-Angle / drug therapy* Humans Intraocular Pressure / drug effects Male Ocular Hypertension / drug therapy* Prospective Studies Prostaglandins F, Synthetic / administration & dosage, adverse effects, therapeutic use* Quinoxalines / administration & dosage, adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Prostaglandins F, Synthetic; 0/Quinoxalines; 130209-82-4/latanoprost; 59803-98-4/brimonidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Celiac plexus block with the long stylet needle technique.
Next Document: Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in hea...